Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma.
[OBJECTIVE] This study aimed to explore factors associated with the likelihood of surgical resection after triple-combination conversion therapy in patients with initially unresectable hepatocellular
- 표본수 (n) 147
- p-value P < 0.05
- 95% CI 0.784-0.915
- OR 0.663
APA
Su Y, Liang Y, et al. (2026). Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma.. European journal of radiology, 197, 112724. https://doi.org/10.1016/j.ejrad.2026.112724
MLA
Su Y, et al.. "Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma.." European journal of radiology, vol. 197, 2026, pp. 112724.
PMID
41707553
Abstract
[OBJECTIVE] This study aimed to explore factors associated with the likelihood of surgical resection after triple-combination conversion therapy in patients with initially unresectable hepatocellular carcinoma (uHCC) and to develop an exploratory predictive model.
[METHODS] A retrospective analysis was conducted using clinical data from 210 patients with uHCC who underwent triple-combination conversion therapy at Sichuan Cancer Hospital between January 2022 and January 2025. Patients were randomly assigned to a training cohort (n = 147) and a validation cohort (n = 63) in a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression was applied to screen candidate predictors, followed by multivariate logistic regression to identify factors associated with surgical conversion. A nomogram was constructed based on these variables, and its discriminative ability, calibration, and potential clinical utility were internally assessed using receiver operating characteristic (ROC) analysis, calibration plots, the Hosmer-Lemeshow test, and decision curve analysis (DCA).
[RESULTS] Among the 210 patients, 47 (22.4%) successfully underwent conversion and radical resection. Multivariate logistic regression analysis suggested that lower tumor burden score (TBS; OR = 0.663), lower neutrophil-to-lymphocyte ratio (NLR; OR = 0.572), lower C-reactive protein-to-albumin ratio (CAR; OR = 0.057), and absence of cirrhosis (OR = 0.289) were associated with a higher likelihood of successful surgical conversion (P < 0.05). The nomogram showed moderate to good discriminative performance, with areas under the ROC curve (AUCs) of 0.850 (95% CI: 0.784-0.915) in the training cohort and 0.871 (95% CI: 0.783-0.962) in the validation cohort. Calibration plots and decision curve analysis provided descriptive information regarding model performance within the study cohort.
[CONCLUSION] The proposed nomogram, incorporating TBS, NLR, CAR, and cirrhosis status, represents an exploratory tool for estimating the probability of surgical conversion following triple-combination therapy in patients with uHCC. While the model may provide supplementary information to support clinical assessment and patient stratification, further multicenter and prospective studies are required to externally validate and refine its performance before broader clinical application.
[METHODS] A retrospective analysis was conducted using clinical data from 210 patients with uHCC who underwent triple-combination conversion therapy at Sichuan Cancer Hospital between January 2022 and January 2025. Patients were randomly assigned to a training cohort (n = 147) and a validation cohort (n = 63) in a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression was applied to screen candidate predictors, followed by multivariate logistic regression to identify factors associated with surgical conversion. A nomogram was constructed based on these variables, and its discriminative ability, calibration, and potential clinical utility were internally assessed using receiver operating characteristic (ROC) analysis, calibration plots, the Hosmer-Lemeshow test, and decision curve analysis (DCA).
[RESULTS] Among the 210 patients, 47 (22.4%) successfully underwent conversion and radical resection. Multivariate logistic regression analysis suggested that lower tumor burden score (TBS; OR = 0.663), lower neutrophil-to-lymphocyte ratio (NLR; OR = 0.572), lower C-reactive protein-to-albumin ratio (CAR; OR = 0.057), and absence of cirrhosis (OR = 0.289) were associated with a higher likelihood of successful surgical conversion (P < 0.05). The nomogram showed moderate to good discriminative performance, with areas under the ROC curve (AUCs) of 0.850 (95% CI: 0.784-0.915) in the training cohort and 0.871 (95% CI: 0.783-0.962) in the validation cohort. Calibration plots and decision curve analysis provided descriptive information regarding model performance within the study cohort.
[CONCLUSION] The proposed nomogram, incorporating TBS, NLR, CAR, and cirrhosis status, represents an exploratory tool for estimating the probability of surgical conversion following triple-combination therapy in patients with uHCC. While the model may provide supplementary information to support clinical assessment and patient stratification, further multicenter and prospective studies are required to externally validate and refine its performance before broader clinical application.
MeSH Terms
Humans; Nomograms; Carcinoma, Hepatocellular; Male; Female; Liver Neoplasms; Middle Aged; Retrospective Studies; Aged; Combined Modality Therapy
같은 제1저자의 인용 많은 논문 (5)
- Corrigendum to "Caffeic acid-grafted chitosan/sodium alginate/nanoclay-based multifunctional 3D-printed hybrid scaffolds for local drug release therapy after breast cancer surgery" [Carbohydrate Polymers 324 (2024) 121441].
- The Effectiveness of Telemedicine-Based Psychosocial Intervention for Fear of Cancer Recurrence, Mindfulness, and Posttraumatic Growth in Cancer Survivors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- The Effectiveness of Telemedicine on Distress, Physical Function and Self-Efficacy in Patients With Cancer: A Meta-Analysis of Randomised Controlled Trials.
- Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series.
- Functional roles of Keratin 6A in disease pathogenesis across cancer and skin disorders.